Ciclopirox HPCH nail lacquer after failure of topical treatment with Amorolfine
Wolfgang Vanscheidt, Wolfgang Schalla
Journal of Dermatology and Clinical Research
Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia
M. Caserini, M. Radicioni, C. Leuratti, E. Terragni, M. Iorizzo, R. Palmieri
International Journal of Clinical Pharmacology and Therapeutics 2015 Dec 4
A Hydroxypropyl Chitosan (HPCH) Based Medical Device Prevents Fungal Infections: Evidences from an In Vitro Human Nail Model
Anna Bulgheroni, Linda Frisenda, Alessandro Subissi, Federico Mailland
The Open Dermatology Journal, 2015, 9, 4-9
Carbocysteine: A New Way for Stretch Marks Treatment
Francesco Scarci, Federico Mailland
Journal of Cosmetics, Dermatological Sciences and Applications, 2015, 5, 275-282
Ciclopirox 8% HPCH nail lacquer in the treatment of mild-to-moderate onychomycosis: a randomized, amorolfine controlled study using a blinded evaluator.
Iorizzo M et al.
Skin Appendage Disorders 2015;1:134-140
Nail Psoriasis in Children: Common or Uncommon? Results from a 10-Year Double-Center Study.
Piraccini BM, Triantafyllopoulou I, Prevezas C, Starace M, Neri I, Patrizi A, Caserini M, Palmieri R, Rigopoulos D.
Skin Appendage Disorders 2015; 1:43-48
Ability of hydroxypropyl-chitosan (HPCH) nail solution to protect against dermatophyte nail infection.
Ghannoum MA, Long L, Isham N, Bulgheroni A, Setaro M, Caserini M, Palmieri R, Mailland F.
Antimicrob Agents and Chemotherapy 2015 Apr; 59(4):1844-8
A Hydroxypropyl Chitosan (HPCH) based medical device prevents fungal infections: evidences from an in vitro human nail model.
Bulgheroni A, Frisenda L, Subissi A, Mailland F.
The Open Dermatology Journal, 2015, 9, 4-9
A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers.
Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R.
International Journal of Clinical Pharmacology and Therapeutics 2014, 52(10):842-849
Topical formulations containing finasteride. Part I: in vitro permeation/penetration study and in vivo pharmacokinetics in hairless rat.
Monti D, Tampucci S, Burgalassi S, Chetoni P, Lenzi C, Pirone A, Mailland F.
Journal of Pharmaceutical Sciences 2014 Aug; 103(8):2307-14
Topical formulations containing finasteride. Part II: determination of finasteride penetration into hair follicles using the differential stripping technique.
Tampucci S, Burgalassi S, Chetoni P, Lenzi C, Pirone A, Mailland F, Caserini M, Monti D.
J Journal of Pharmaceutical Sciences 2014 Aug; 103(8):2323-9
Randomised, controlled trial of a water-soluble nail lacquer based on hydroxypropyl-chitosan (HPCH), in the management of nail psoriasis.
Cantoresi F, Caserini M, Bidoli A, Maggio F, Marino R, Carnevale C, Sorgi P, Palmieri R.
Clinical, Cosmetic and Investigational Dermatology 2014; 7:185-190
Ciclopirox vs Amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers.
Monti D, Tampucci S, Chetoni P, Burgalassi S, Mailland F.
Journal of Drugs in Dermatology, 2014, Vol. 13 Issue 2
Effects of a novel nail lacquer based on hydroxypropyl-chitosan (HPCH) in subjects with fingernail onychoschizia.
Sparavigna A, Caserini M, Tenconi B, De Ponti I, Palmieri R.
Journal of Dermatology and Clinical Research 2014; 2(2):1013
The protective efficacy of a new hydroxypropyl chitosan-based medical device in subjects at risk of onychomycosis.
Chimenti S., Difonzo E., Aste N., Frisenda L., Caserini M.
Journal of Plastic Dermatology 2013; 9, 3.
A new medical device based on hydroxypropyl-chitosan improves the nail structure in subjects with onychodystrophy.
Iorizzo M, Palmieri R.
Journal of Plastic Dermatology 2013; 9(3):203-207
Efficacy of Vitamin C vaginal tablets as prophylaxis for recurrent bacterial vaginosis: a randomized, double blind, placebo-controlled clinical trial.
Krasnopolsky VN, Prilepskaya VN, Polatti F, Zarochentseva NV, Bayramova GR, Caserini M, Palmieri R.
Journal of Clinical Medicine Research 2013; 5(4):309-315
Instrumental assessment of the soothing effect of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate.
Celleno L, Bussoletti C, Caserini M, Palmieri R.
Journal of Plastic Dermatology 2012; 8(1):33-35
Assessment of the antidandruff activity of a new shampoo: a randomized, double-blind, controlled study by clinical and instrumental evaluations.
Sparavigna A, Setaro M, Caserini M, Bulgheroni A.
Skinmed. 2013 Mar-Apr;11(2):85-91
Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea.
Berardesca E, Iorizzo M, Abril E, Guglielmini G, Caserini M, Palmieri R, Piérard G.
Journal of Cosmetic Dermatology 2012; 11(1):37 – 41
An Innovative Concept Gel to Prevent Skin Aging.
Sparavigna A, Tenconi B, Deponti I, Scarci F, Caserini M, Mailland F.
Journal of Cosmetics, Dermatological Sciences and Applications, 2013, 3, 271-280
Bacterial vaginosis, atopobium vaginae and nifuratel.
Polatti F.
Current Clinical Pharmacology 2012; 7(1):36-40
In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis?
Togni G, Battini V, Bulgheroni A, Mailland F, Caserini M, Mendling W.
Antimicrob Agents Chemother 2011; 55(5):2490-2492
Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation.
Monti D, Saccomani L, Chetoni P, Burgalassi S, Tampucci S and Mailland F.
British Journal of Dermatology 2011 165, pp99–105
A comparative effectiveness of nifuratel and metronidazole in therapy of bacterial vaginosis associated with atopobium vaginae.
Perlamutrov YN, Gomberg MA, Chernova NI, Bochkova OI, Shcherbo SN.
Problems of Gynecology, Obstetrics and Perinatology 2011, 10 (3): 22-25
Efficacy of vitamin C vaginal tablets in the treatment of bacterial vaginosis: a randomized, double blind, placebo controlled clinical trial.
Petersen EE., Genet M., Caserini M., Palmieri R.
Arzeimittelforschung 2011; 61(4):260-265
Antifungal Activity, Experimental Infections and Nail Permeation of an. Innovative Ciclopirox Nail Lacquer Based on a Water-soluble Biopolymer.
Togni G., Mailland F.
Journal of drugs in Dermatology, May 2010, Vol 9, issue 5
Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
Monti D., Saccomani L., Chetoni P., Burgalassi S., Senesi S., Ghelardi E., Mailland F.
British Journal of Dermatology 2010 162, pp 311–317
An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis.
Baran R, Tosti A, Hartmane I, Altmeyer P, Hercogova J, Koudelkova V, Ruzicka T, Combemale P, Mikazans I.
J Eur Acad Dermatol Venereol. 2009 Jul;23(7):773-81
Physical and microbiological properties of a new nail protective medical device.
Sparavigna A, Setaro M, Frisenda L.
Journal of Plastic Dermatology- 2008, 4, 1
Equisetum arvense in a new transungual technology improves nail structure and appearance.
Sparavigna A, Setaro M, Genet M, Frisenda L.
Journal of Plastic Dermatology Jan – Apr. 2006,Vol 2, n.1
In vitro Antimycotic Activity and Nail Permeation Models of a Piroctone Olamine (Octopirox) Containing Transungual Water SolubleTechnology.
Dubini F, Bellotti MG, Frangi A, Saettone MF, Monti D, Saccomani L..
Arzneim.-Forsch/Drug 2005, Res.55, No.8, 478-483
In vitro antimycotic activity and biological assay of nail permeation of a new climbazole/octopirox hydrolacquer.
Frangi A, Colì A..
Journal of Plastic Dermatology September-December 2005, Vol.1, n.3,.
Computerized image analysis of nails affected by fungal infection: evaluation using digital photographs and manually defined areas.
Baran R, Sparavigna A, Setaro M, Mailland F.
Journal of Drug In Dermatology, 2004; 3 (5):489-494
Clinical study on the dose-effect relationship of nifuratel-nystatin combination in the treatment of vulvo-vaginal Infections.
Polatti F, Nappi RE, Brundu B, Fantuzzi M, Frisenda L.
Arzneim.-Forsch/Drug 2003, Res 53, No. 10,730-737
ABSTRACTS & POSTERS
Onychomycosis severity and/or subject’s age does influence the performance of an antifungal drug: data of P-3058 10%, a terbinafine nail solution.
Tosti A, Piraccini BM, Caserini M, Frisenda L.
Summer AAD, 19-23 August 2015, New York, USA.
Ciclopirox 8% hydrolacquer once a day versus amorolfine 5% twice a week administered in mild-to-moderate onychomycosis: a randomized, parallel group, blinded assessor trial.
Iorizzo M, Mikazans I, Hartmane I, Derveniece A, Frisenda L.
12th EADV Spring, 5-8 March 2015, Valencia, Spain.
Pharmacokinetic profile of P-3058, a new terbinafine nail solution, in patients with onychomycosis.
Frisenda L, Hartmane I, Mikazans I, Derveniece A, Caserini M.
12th EADV Spring, 5-8 March 2015, Valencia, Spain.
Effects of P-3074, a topical solution of finasteride in the treatment of androgenetic alopecia.
Caserini M, Scarci F, Palmieri R.
45th Annual ESDR Meeting – Rotterdam – 9/12 September 2015
Nifuratel: an effective drug in bacterial vaginosis treatment.
Gomberg MA, Chernova NI
29th IUSTI Europe Congress – Barcelona – 24/26 September 2015
Efficacy of Nifuratel in Trichomonas vaginalis treatment.
Chernova Ni, Gomberg MA
29th IUSTI Europe Congress – Barcelona – 24/26 September 2015
P-3073: a novel topical nail solution in the treatment of nail psoriasis.
Rigopoulos D, Iorizzo M, Caserini M, Palmieri R.
24th EADV Congress – Copenhagen – 07/11 October 2015
An innovative terbinafine transungual solution (P-3058): A phase 2b dose finding study in patients with mild to moderate onychomycosis.
Baran R, Mailland F, Frisenda L, Caserini M.
American Academy of Dermatology, 72nd Annual Meeting, March 21-25, 2014, Denver, Colorado.
Measuring health-related quality of life in patients with nail disorders: development and validation of the nail disease quality of life (NDQoL)
Cantoresi F, Bidoli A, Cantisani C, Filograna S, Palmieri R, Caserini M, Pisanti R
23th EADV Congress – Amsterdam – 09/12 October 2014
Activity of P-3075, a new medical device based on potassium azeloyl diglycinate, in the treatment of acne vulgaris.
Sparavigna A, Caserini M, Palmieri R.
11th EADV Spring Symposium – Belgrade – 22/24 May 2014
Evaluation of efficacy rate of an innovative ciclopirox 8% HPCH hydrolacquer in onychomycotic patients who previously failed amorolfine 5% treatment.
Caserini M, Bonizzoni E, Scarci F, Mailland F, Frisenda L.
22th EADV 2-6 October 2013, Istanbul, Turkey
Onychomycosis topical treatments: a comparison.
Caserini M., Bonizzoni E., Frisenda L., Mailland F.
22th EADV 2-6 October 2013, Istanbul, Turkey
Single and repeated dose of finasteride topical solution in subjects with androgenetic alopecia: a pharmacokinetic and pharmacodynamic study.
Caserini M, Annoni O, Radicioni M, Palmieri R, Mailland F
71st Annual Meeting AAD – Miami Beach – 01/05 March 2013
Pharmacodynamic of P-3074 (finasteride 0.25% topical solution) in subjects with androgenetic alopecia.
Caserini M, Palmieri R, Radicioni M, Terragni E
7th World Congress for Hair Research – Edinburgh – 04/06 Maggio 2013
A comparison among commonly used nail products on nail mechanical properties.
Mailland F, Setaro M, Palmieri R, Catena M, Caserini M.
71st Annual Meeting AAD – Miami Beach – 01/05 March 2013
A randomized, double-blind, controlled study to assess the efficacy and safety of Nifuratel in the treatment of trichomoniasis.
Mendling W, Caserini M, Palmieri R.
STI & AIDS World Congress – Vienna – 14/17 July 2013
A randomized, controlled study to assess the efficacy and safety of Nifuratel vaginal tablets on bacterial vaginosis.
Mendling W, Caserini M, Palmieri R.
STI & AIDS World Congress – Vienna – 14/17 July 2013
The susceptibility of Trichophyton rubrum clinical isolates to ciclopirox is not influenced by geographical factors.
Ghannoum M, Isham N, Frisenda L, Bulgheroni A.
21st EADV, 27-30 Sept 2012, Prague, Czech Republic
Ciclopirox and Amorolfine permeation/penetration through human nails.
Monti D., Tampucci S., Caserini M., Frisenda L.
9th EADV Spring, 6-10 June 2012, Verona, Italy.
Pharmacokinetics and pharmacodynamic of finasteride topical solution after single and repeated dose in subjects with androgenetic alopecia.
Caserini M, Radicioni M, Annoni O, Palmieri R
42nd Annual ESDR Meeting – Venezia – 19/22 September 2012
Permeation and distribution of finasteride through hairless rat skin: in vitro study.
Monti D, Tampucci S, Burgalassi S, Chetoni P, Caserini M, Mailland F.
42nd Annual ESDR Meeting – Venezia – 19/22 September 2012
Pharmacokinetic study in hairless rat after topical application of finasteride: single and repeated dose.
Mailland F, Tampucci S, Burgalassi S, Chetoni P, Caserini M, Monti D.
42nd Annual ESDR Meeting – Venezia – 19/22 September 2012
Determination of topically applied finasteride penetrated into hair follicles by using the differential stripping technique.
Tampucci S, Burgalassi S, Chetoni P, Mailland F, Caserini M, Monti D.
42nd Annual ESDR Meeting – Venezia – 19/22 September 2012
Effect of a medical device based on hydroxypropyl-chitosan on nail psoriasis.
Cantoresi F, Caserini M, Palmieri R.
Summer AAD – Boston – 15/19 August 2012
Controlled study on the effect of P-3075 (potassium azeloyl diglycinate, PAD) on the microcirculation flow in patients with rosacea.
Sparavigna A, Caserini M, Palmieri R.
Summer AAD – Boston – 15/19 August 2012
Efficacy on nail psoriasis of a medical device base on hydroxypropyl-chitosan.
Cantoresi F, Palmieri R, Caserini M.
9th EADV Spring Symposium – Verona – 6/10 June 2012
Activity of P-3075, a new medical device based on potassium azeloyl diglycinate, on the microcirculation in patients with rosacea.
Sparavigna A., Palmieri R, Caserini M.
9th EADV Spring Symposium – Verona – 6/10 June 2012
Nail mechanical properties after application of a medical device based on hydroxypropyl chitosan.
Mailland F, Setaro M, Palmieri R, Catena M, Caserini M.
Skin & Formulation 4° Symposium – Lyon – 4/5 June 2012
A double-blind, placebo-controlled study to assess the efficacy of vitamin C vaginal tablets as prophylaxis of bacterial vaginosis recurrence.
Prilepskaya VN, Krasnopolsky VN, Bayramova GR, Zarochintseva NV, Palmieri R.
26th IUSTI Europe Congress – Riga – 08/10 September 2011
Nail penetration of topical antifungal drugs in healthy subjects.
Frisenda L., Bulgheroni A., Caserini M.
7th EADV Spring, Cavtat (Croatia), 13-16 May 2010
Evaluation of the protective effect of P-3063, a new medical device based on a hydroxypropyl chitosan lacquer, in subjects with nail alterations at risk of onychomycosis.
Iorizzo M., Palmieri R., Frisenda L.
Winter Academy of dermatology. St. Moritz and Pontresina – April 8-11, 2010
Physical Properties of a New Hydroxypropyl-Chytosan Biopolymer.
Ceriani D, Frisenda L, Caserini M, Mailland F.
European Chitin Society, Venezia, 23-26 May 2009
Computerized assessment of human nail growth rate after a new hydroxypropyl-chytosan biopolymer application.
Ceriani D, Frisenda L, Caserini M, Mailland F.
European Chitin Society, Venezia, 23-26 May 2009
Physical properties of an innovative nail protective hydrolacquer.
Mailland F., Sparavigna A., Setaro M.
AAD 67th Annual meeting, S. Francisco, CA, 6-10 March 2009
Barrier effect of a film forming medical device based on Hydroxypropyl chitosan (Myfungar®)”.
Togni G., Vallefuoco R., Caserini M., Mailland F.
10th International Congress of Dermatology (ICD), Prague, 20-24 May 2009
Hydroxypropyl-chitosan accelerates nail growth both in healthy fingernails and in mycotic toenails.
Baran R, Sparavigna A, Setaro M, Mailland F, Frisenda L.
World Dermatology Congress in Buenos Aires, October 2007
Ciclopirox nail concentrations in vitro and after single and multiple applications on healthy fingernails of a hydroxypropyl-chitosan based nail lacquer.
Mailland F, Dal Bo L, Frisenda L.
World Dermatology Congress in Buenos Aires, October 2007
Computerised image analysis in the assessment of human nail growth rate.
Sparavigna A, Setaro M, Mailland F.
ESDR, May 2007
Structure and mechanism of adherence to the nail surface of a film formed by hydroxypropyl chitosan.
Legora M, Mailland F.
EADV, Vienna, May 2007